In addition to ABC DLBCL, MALT1 protease inhibition might also be beneficial for patients suffering from other lymphoid malignancies relying on constitutive CBM signaling or aberrant MALT1 protease activity, such as MCL and CLL as well as MALT lymphomas expressing the cIAP2-MALT1 fusion [150,151,152,153]. The gene discussed is BIRC3; the disease is MALT lymphoma.